Radiation Oncology
Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.
Recent Discussions
In what scenario would you add systemic therapy with adjuvant radiation therapy in resected, locally-advanced, cutaneous squamous cell carcinoma?
This is an active area in clinical trials, here is a recently published reviewNewman et al., PMID 34096664 More to come in a future post, I will see what trials are currently available in the Chicago area!
Would you recommend adjuvant radiotherapy for recurrent paraganglioma with lymph node involvement treated with salvage neck dissection with no residual disease?
If no prior radiation, yes with carcinoma doses. If prior RT, it would depend on whether there or multiple nodes. If not, no. If yes, I would consider more radiation.
Why do we use dexamethasone for CNS edema and prednisone for pneumonitis?
Dexamethasone has better CNS penetration compared to prednisone and thus its established use for managing vasogenic edema. However, it has the most suppressive effect on ACTH, causes relatively more steroid myopathy and has less mineralocorticoid effect compared to prednisone hence, the general use ...
Would you consider SBRT or more conventionally fractionated radiation for an in-field mediastinal recurrence of esophageal adenocarcinoma s/p preoperative CRT, esophagectomy, and now progressing on immunotherapy?
Hard question – many variables (and answers). I think the timing of recurrence and overlap/proximity to central structures (and extent of overlap to prior RT) biggest determinants of fractionation and whether to offer RT at this junction (i.e., if ‘ultra-central’ location, would certainly consider h...
For locally advanced NSCLC with additional synchronous NSCLC primaries in the same lung or lobe, what is your approach to definitive therapy?
This is a situation that comes up surprisingly frequently and can be challenging to navigate. This assumes that one is certain which of the two lung lesions is the primary (i.e. based on discordant pathology or genomic profiling results of the nodal metastasis and/or first primary compared to the se...
How do you sequence I-131 and external beam radiation therapy after thyroidectomy for locally advanced thyroid cancer?
I've not had an occasion wherein I sequence a radiopharmaceutical and XRT for thyroid cancer, as a planned event. Again, different indications for different therapeutics here. The radioisotope is designed to address I-avid, minimal volume disease while XRT is designed to treat macroscopic, generally...
How would you treat a prostate cancer with malignant priapism due to direct tumor extension?
Carefully! No seriously, this is a case where MRI imaging and the utilization of complete androgen blockade can make a big difference. Also coordination with urology. I've treated one patient in this circumstance, and luckily for him, he did get symptomatic relief with LHRH antagonist (which I would...
Would you consider lymph node basin radiation in a patient with upper extremity Merkel cell carcinoma with one positive SLN but with no other positive lymph nodes found on axillary dissection?
Yes. My preference would have been to obtain a PET, excise the positive node, and irradiate the axilla to reduce the risk of arm edema.
How do you account for only a partial fraction of radiation being delivered due to machine malfunction?
For conventional fractionation, I have typically disregarded this partial dose and repeated that fraction at full dose unless it was >75%. For SBRT, in one case, half the dose was delivered in one arc. and the next day once the problem was fixed the patient received the second arc to complete that f...
What are your top takeaways from ASCO GU 2022?
My top abstracts and questions that arise from them: 1) ARASENS with darolutamide in high volume de novo mHSPC showing an OS benefit with darolutamide over ADT/docetaxel. Will this pertain only to high volume/risk patients who are chemo-fit and de novo which seemed to comprise the vast majority of ...